Drug intelligence / Profile preview

Undisclosed RAS Pathway Program

Development stage: Preclinical
Lead developer: GenFleet Therapeutics
Modality: Small Molecules

Overview

The Undisclosed RAS Pathway Program consists of small molecule drug candidates being developed by GenFleet Therapeutics in collaboration with Verastem Oncology. These programs target undisclosed components of the RAS signaling pathway, which is a critical driver in various malignancies. The research is currently in the discovery and preclinical stages, focusing on the treatment of advanced solid tumors, including pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. This collaboration expands on the partnership between the two companies, which also includes the KRAS G12D inhibitor VS-7375.

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on Undisclosed RAS Pathway Program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Undisclosed RAS Pathway Program.

Explore the full profile